NO20066017L - Azaindoler - Google Patents

Azaindoler

Info

Publication number: NO20066017L
Authority: NO; Norway
Prior art keywords: azaindoles
Prior art date: 1999-12-24

Application number

NO20066017A

Other languages

English (en)

Other versions

NO330747B1 (no

Inventor

Andrew David Morley

Paul Joseph Cox

Tahir Nadeem Majid

Justine Yeun Quai Lai

Shelley Amendola

Stephanie Deprets

Chris Edlin

Original Assignee

Aventis Pharma Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-24

Filing date

2006-12-27

Publication date

2002-06-21

1999-12-24 Priority claimed from GBGB9930698.7A external-priority patent/GB9930698D0/en

2002-06-21 Publication of NO20066017L publication Critical patent/NO20066017L/no

2006-12-27 Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd

2011-07-04 Publication of NO330747B1 publication Critical patent/NO330747B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Oncology (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)

NO20066017A 1999-12-24 2006-12-27 Farmasoytiske sammensetninger omfattende azaindoler, forbindelser som er azaindoler samt anvendelse derav. NO330747B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9930698.7A GB9930698D0 (en)	1999-12-24	1999-12-24	Chemical compounds
US21581800P	2000-07-05	2000-07-05
PCT/GB2000/004993 WO2001047922A2 (en)	1999-12-24	2000-12-27	Azaindoles

Publications (2)

Publication Number	Publication Date
NO20066017L true NO20066017L (no)	2002-06-21
NO330747B1 NO330747B1 (no)	2011-07-04

Family

ID=26316153

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20023032A NO323766B1 (no)	1999-12-24	2002-06-21	Azaindoler, farmasoytiske sammensetninger innbefattende og deres anvendelse for fremstilling av medikament
NO20066017A NO330747B1 (no)	1999-12-24	2006-12-27	Farmasoytiske sammensetninger omfattende azaindoler, forbindelser som er azaindoler samt anvendelse derav.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO20023032A NO323766B1 (no)	1999-12-24	2002-06-21	Azaindoler, farmasoytiske sammensetninger innbefattende og deres anvendelse for fremstilling av medikament

Country Status (27)

Country	Link
US (2)	US6770643B2 (no)
EP (2)	EP1263759B1 (no)
JP (1)	JP5436507B2 (no)
KR (2)	KR100910488B1 (no)
CN (2)	CN100379734C (no)
AP (2)	AP1917A (no)
AU (1)	AU777717B2 (no)
BG (2)	BG66066B1 (no)
BR (1)	BR0017038A (no)
CA (2)	CA2699568C (no)
CY (1)	CY1110951T1 (no)
CZ (2)	CZ301751B6 (no)
DZ (1)	DZ3377A1 (no)
EA (1)	EA005212B1 (no)
EE (1)	EE05180B1 (no)
HK (1)	HK1050191B (no)
HR (1)	HRP20020547B1 (no)
HU (1)	HUP0203895A3 (no)
IL (3)	IL150388A0 (no)
MA (1)	MA26857A1 (no)
MX (1)	MXPA02006338A (no)
NO (2)	NO323766B1 (no)
NZ (1)	NZ519121A (no)
OA (1)	OA12514A (no)
PL (1)	PL209572B1 (no)
SK (2)	SK288019B6 (no)
WO (1)	WO2001047922A2 (no)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2679459B2 (ja)	1991-08-02	1997-11-19	王子製紙株式会社	感熱記録体
NZ519121A (en)	1999-12-24	2004-05-28	Aventis Pharma Ltd	Azaindoles useful as Syk kinase inhibitors
EP1363705B9 (en) *	2001-02-02	2012-11-07	Bristol-Myers Squibb Company	Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
GB0108770D0 (en)	2001-04-06	2001-05-30	Eisai London Res Lab Ltd	Inhibitors
GB0115109D0 (en) *	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
WO2003000690A1 (en) *	2001-06-25	2003-01-03	Aventis Pharmaceuticals Inc.	Synthesis of heterocyclic compounds employing microwave technology
EP2335700A1 (en) *	2001-07-25	2011-06-22	Boehringer Ingelheim (Canada) Ltd.	Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US20030158195A1 (en)	2001-12-21	2003-08-21	Cywin Charles L.	1,6 naphthyridines useful as inhibitors of SYK kinase
US6884889B2 (en) *	2002-03-25	2005-04-26	Bristol-Myers Squibb Co.	Processes for the preparation of antiviral 7-azaindole derivatives
JP2005534619A (ja) *	2002-03-28	2005-11-17	エーザイ株式会社	Ｃ−ｊｕｎｎ−末端キナーゼ阻害剤としてのアザインドール
EP1490364B1 (en) *	2002-03-28	2007-09-26	Eisai R&D Management Co., Ltd.	7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
US20050124620A1 (en) *	2002-04-09	2005-06-09	Martyn Frederickson	Pharmaceutical compounds
WO2003087087A2 (en) *	2002-04-09	2003-10-23	Astex Technology Limited	Heterocyclic compounds and their use as modulators of p38 map kinase
TW200307542A (en) *	2002-05-30	2003-12-16	Astrazeneca Ab	Novel compounds
SE0201635D0 (sv)	2002-05-30	2002-05-30	Astrazeneca Ab	Novel compounds
SE0202241D0 (sv)	2002-07-17	2002-07-17	Astrazeneca Ab	Novel Compounds
EP1388541A1 (en) *	2002-08-09	2004-02-11	Centre National De La Recherche Scientifique (Cnrs)	Pyrrolopyrazines as kinase inhibitors
EP1545515A1 (en)	2002-08-12	2005-06-29	Sugen, Inc.	3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
SE0202464D0 (sv) *	2002-08-14	2002-08-14	Astrazeneca Ab	Use of compounds
AU2003303678A1 (en) *	2003-01-03	2004-08-10	Genzyme Corporation	Urea derivatives and their use as anti-inflammatory agents
US7223785B2 (en)	2003-01-22	2007-05-29	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
US7098231B2 (en) *	2003-01-22	2006-08-29	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
EP2295433A3 (en) *	2003-03-06	2011-07-06	Eisai R&D Management Co., Ltd.	JNK inhibitors
GB0305142D0 (en)	2003-03-06	2003-04-09	Eisai London Res Lab Ltd	Synthesis
SE0300908D0 (sv)	2003-03-31	2003-03-31	Astrazeneca Ab	Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
SE0301372D0 (sv) *	2003-05-09	2003-05-09	Astrazeneca Ab	Novel compounds
US7612086B2 (en)	2003-05-16	2009-11-03	Eisai R & D Management Co. Ltd.	JNK inhibitors
SE0301569D0 (sv)	2003-05-27	2003-05-27	Astrazeneca Ab	Novel compounds
KR20130023381A (ko)	2003-07-17	2013-03-07	플렉시콘, 인코퍼레이티드	Ｐｐａｒ 활성 화합물
SE0302232D0 (sv)	2003-08-18	2003-08-18	Astrazeneca Ab	Novel Compounds
SE0303180D0 (sv) *	2003-11-26	2003-11-26	Astrazeneca Ab	Novel compounds
US7572914B2 (en)	2003-12-19	2009-08-11	Takeda Pharmaceutical Company Limited	Kinase inhibitors
UY28758A1 (es)	2004-02-20	2005-09-30	Boehringer Ingelheim Int	Inhibidores de polimerasa viral
FR2868422B1 (fr)	2004-03-31	2006-07-14	Aventis Pharma Sa	Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2005105788A1 (en) *	2004-04-23	2005-11-10	Takeda San Diego, Inc.	Indole derivatives and use thereof as kinase inhibitors
WO2006023931A2 (en)	2004-08-18	2006-03-02	Takeda San Diego, Inc.	Kinase inhibitors
FR2876103B1 (fr)	2004-10-01	2008-02-22	Aventis Pharma Sa	Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2006044687A2 (en)	2004-10-15	2006-04-27	Takeda San Diego, Inc.	Kinase inhibitors
AR054416A1 (es)	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
CA2589877A1 (en) *	2004-12-23	2006-06-29	F. Hoffmann-La Roche Ag	Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
CN101087787A (zh) *	2004-12-23	2007-12-12	霍夫曼-拉罗奇有限公司	苯甲酰胺衍生物，它们的制备及作为药剂的应用
GB0500604D0 (en)	2005-01-13	2005-02-16	Astrazeneca Ab	Novel process
US20060183758A1 (en) *	2005-02-17	2006-08-17	Cb Research And Development, Inc.	Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
WO2006127587A1 (en)	2005-05-20	2006-11-30	Vertex Pharmaceuticals Incorporated	Pyrrolopyridines useful as inhibitors of protein kinase
CN102127078A (zh) *	2005-07-14	2011-07-20	安斯泰来制药株式会社	Janus激酶3的杂环类抑制剂
EP1910358A2 (en) *	2005-07-14	2008-04-16	Astellas Pharma Inc.	Heterocyclic janus kinase 3 inhibitors
GB0516156D0 (en)	2005-08-05	2005-09-14	Eisai London Res Lab Ltd	JNK inhibitors
JP5015154B2 (ja) *	2005-08-12	2012-08-29	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ウイルスポリメラーゼインヒビター
EP2270014A1 (en)	2005-09-22	2011-01-05	Incyte Corporation	Azepine inhibitors of janus kinases
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
EP1963320A1 (en) *	2005-12-07	2008-09-03	OSI Pharmaceuticals, Inc.	Pyrrolopyridine kinase inhibiting compounds
UA116187C2 (uk) *	2005-12-13	2018-02-26	Інсайт Холдінгс Корпорейшн	ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
JP5140600B2 (ja) *	2005-12-23	2013-02-06	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	オーロラキナーゼのアザインドール阻害薬
JP2009523812A (ja) *	2006-01-19	2009-06-25	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	融合へテロ二環式キナーゼ阻害剤
AU2007254179B2 (en) *	2006-05-18	2013-03-21	Pharmacyclics Llc	Intracellular kinase inhibitors
JP2009538289A (ja)	2006-05-26	2009-11-05	アストラゼネカ・アクチエボラーグ	ビアリールまたはヘテロアリール置換インドール
WO2008014249A2 (en) *	2006-07-24	2008-01-31	Sanofi-Aventis	Improved preparations of 2 -substituted pyrrolo [2, 3-b] pyrazine ( 4, 7 -diazaindole ) compounds
GB0617161D0 (en) *	2006-08-31	2006-10-11	Vernalis R&D Ltd	Enzyme inhibitors
CL2007002617A1 (es)	2006-09-11	2008-05-16	Sanofi Aventis	Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
EP2223925A1 (en) *	2006-10-09	2010-09-01	Takeda Pharmaceutical Company Limited	Kinase inhibitors
BRPI0719883A2 (pt)	2006-10-09	2015-05-05	Takeda Pharmaceutical	Inibidores de quinase
EP2121692B1 (en)	2006-12-22	2013-04-10	Incyte Corporation	Substituted heterocycles as janus kinase inhibitors
CL2008001709A1 (es)	2007-06-13	2008-11-03	Incyte Corp	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
WO2008157208A2 (en)	2007-06-13	2008-12-24	Incyte Corporation	Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8309718B2 (en) *	2007-11-16	2012-11-13	Incyte Corporation	4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
ATE522534T1 (de) *	2008-02-25	2011-09-15	Hoffmann La Roche	Pyrrolopyrazin-kinasehemmer
JP5529049B2 (ja)	2008-02-25	2014-06-25	エフ．ホフマン−ラロシュアーゲー	ピロロピラジンキナーゼ阻害剤
BRPI0907928A2 (pt)	2008-02-25	2015-07-28	Hoffmann La Roche	Inibidores de pirrolopirazina quinase.
MX2010008198A (es) *	2008-02-25	2010-08-23	Hoffmann La Roche	Inhibidores de cinasa de pirrolopirazina.
CN101945877B (zh)	2008-02-25	2013-07-03	霍夫曼-拉罗奇有限公司	吡咯并吡嗪激酶抑制剂
KR20110009084A (ko) *	2008-03-10	2011-01-27	사노피-아벤티스	눈-관련된 장애의 치료방법
NZ587928A (en)	2008-03-11	2012-08-31	Incyte Corp	Azetidine and cyclobutane derivatives as jak inhibitors
US8871753B2 (en) *	2008-04-24	2014-10-28	Incyte Corporation	Macrocyclic compounds and their use as kinase inhibitors
CL2009001884A1 (es) *	2008-10-02	2010-05-14	Incyte Holdings Corp	Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010046215A2 (en) *	2008-10-21	2010-04-29	Syngenta Participations Ag	Diaza-indole derivatives and their use as fungicides
US8765727B2 (en) *	2009-01-23	2014-07-01	Incyte Corporation	Macrocyclic compounds and their use as kinase inhibitors
US20110112101A1 (en) *	2009-03-05	2011-05-12	Sanofi-Aventis	Treatment for ocular-related disorders
AR075869A1 (es) *	2009-03-19	2011-05-04	Sanofi Aventis	Sintesis de azaindoles
PE20120371A1 (es)	2009-05-22	2012-05-17	Incyte Corp	3-[4-(7h-pirrolo[2,3-d]pirimidin-4il)-1h-pirazol-1-il]octano o heptano-nitrilo como inhibidores de jak
EP2432555B1 (en) *	2009-05-22	2014-04-30	Incyte Corporation	N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2454262B1 (en) *	2009-07-15	2014-05-14	Abbott Laboratories	Pyrrolopyrazine inhibitors of kinases
US8816085B2 (en)	2009-08-26	2014-08-26	Takeda Gmbh	Methylpyrrolopyridinecarboxamides
TW201113285A (en) *	2009-09-01	2011-04-16	Incyte Corp	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
MX2012004180A (es)	2009-10-09	2012-07-17	Incyte Corp	Derivados de hidroxil, ceto y glucuronido de 3-(4-7h-pirrolo[2,3-d ]pirimidin-a-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo.
EP2338890A1 (en)	2009-12-22	2011-06-29	Bayer CropScience AG	4,7-Diazaindole derivatives and their use as fungicides
US20110207754A1 (en) *	2010-02-18	2011-08-25	Incyte Corporation	Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
WO2011109932A1 (en) *	2010-03-09	2011-09-15	F.Hoffmann-La Roche Ag	Novel process for the manufacture of 5-halogenated-7-azaindoles
DK3354652T3 (da)	2010-03-10	2020-05-18	Incyte Holdings Corp	Piperidin-4-yl azetidinderivativer som jak1-inhibitorer
US8481541B2 (en)	2010-03-22	2013-07-09	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
US8518945B2 (en)	2010-03-22	2013-08-27	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
TWI496785B (zh)	2010-05-20	2015-08-21	Hoffmann La Roche	吡咯并吡激酶抑制劑
PE20130216A1 (es)	2010-05-21	2013-02-27	Incyte Corp	Formulacion topica para un inhibidor de jak
PH12013501001A1 (en)	2010-11-19	2019-09-02	Incyte Holdings Corp	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EP2640725B1 (en)	2010-11-19	2015-01-07	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CN103732226B (zh)	2011-02-18	2016-01-06	诺瓦提斯药物公司	mTOR/JAK抑制剂组合疗法
JP2014513687A (ja)	2011-05-10	2014-06-05	メルク・シャープ・アンド・ドーム・コーポレーション	Ｓｙｋ阻害薬としてのピリジルアミノピリジン
US9145391B2 (en)	2011-05-10	2015-09-29	Merck Sharp & Dohme Corp.	Bipyridylaminopyridines as Syk inhibitors
WO2012154519A1 (en)	2011-05-10	2012-11-15	Merck Sharp & Dohme Corp.	Aminopyrimidines as syk inhibitors
AR086983A1 (es)	2011-06-20	2014-02-05	Incyte Corp	Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
CA2844507A1 (en)	2011-08-10	2013-02-14	Novartis Pharma Ag	Jak pi3k/mtor combination therapy
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
DE102011111400A1 (de) *	2011-08-23	2013-02-28	Merck Patent Gmbh	Bicyclische heteroaromatische Verbindungen
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
US9216173B2 (en)	2011-10-05	2015-12-22	Merck Sharp & Dohme Corp.	2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
WO2013052391A1 (en)	2011-10-05	2013-04-11	Merck Sharp & Dohme Corp.	PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2763975B1 (en)	2011-10-05	2016-04-06	Merck Sharp & Dohme Corp.	3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
ES2606638T3 (es) *	2012-02-21	2017-03-24	Merck Patent Gmbh	Derivados de furopiridina
AR091079A1 (es)	2012-05-18	2014-12-30	Incyte Corp	Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
EP2863914B1 (en)	2012-06-20	2018-10-03	Merck Sharp & Dohme Corp.	Pyrazolyl derivatives as syk inhibitors
WO2013192128A1 (en)	2012-06-20	2013-12-27	Merck Sharp & Dohme Corp.	Imidazolyl analogs as syk inhibitors
WO2013192098A1 (en)	2012-06-22	2013-12-27	Merck Sharp & Dohme Corp.	SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2863915B1 (en)	2012-06-22	2017-12-06	Merck Sharp & Dohme Corp.	SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
BR112015001545B1 (pt)	2012-07-26	2022-07-05	Glaxo Group Limited	Composto, composição farmacêutica, e, uso de um composto
WO2014031438A2 (en)	2012-08-20	2014-02-27	Merck Sharp & Dohme Corp.	SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9586931B2 (en)	2012-09-28	2017-03-07	Merck Sharp & Dohme Corp.	Triazolyl derivatives as Syk inhibitors
NZ708157A (en)	2012-11-15	2019-07-26	Incyte Holdings Corp	Sustained-release dosage forms of ruxolitinib
SMT201900081T1 (it)	2013-03-06	2019-05-10	Incyte Holdings Corp	Procedimenti e intermedi per produrre un inibitore di jak
WO2014139328A1 (en) *	2013-03-14	2014-09-18	Abbvie Inc.	Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
EP2970264A1 (en)	2013-03-14	2016-01-20	AbbVie Inc.	Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
RU2680100C9 (ru) *	2013-03-15	2019-04-18	Плексксикон Инк.	Гетероциклические соединения и их применения
US20140303121A1 (en)	2013-03-15	2014-10-09	Plexxikon Inc.	Heterocyclic compounds and uses thereof
HRP20200955T1 (hr)	2013-08-07	2020-10-02	Incyte Corporation	Dozni oblici s produženim oslobađanjem za jak1 inhibitor
WO2015184305A1 (en)	2014-05-30	2015-12-03	Incyte Corporation	TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
CN112375067B (zh) *	2014-12-11	2024-03-15	贝达医药公司	取代的2-苯胺基嘧啶衍生物及其作为表皮生长因子受体调节剂
RU2018123825A (ru)	2015-12-07	2020-01-15	Плексксикон Инк.	Соединения и способы для модуляции киназ, и показания для этого
WO2017151409A1 (en)	2016-02-29	2017-09-08	University Of Florida Research Foundation, Incorporated	Chemotherapeutic methods
US20200071326A1 (en) *	2017-04-14	2020-03-05	Syros Pharmaceuticals, Inc.	Tam kinase inhibitors
US10428067B2 (en)	2017-06-07	2019-10-01	Plexxikon Inc.	Compounds and methods for kinase modulation
EP3638241B1 (en)	2017-06-16	2022-05-25	Beta Pharma, Inc.	Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
JP7675519B2 (ja)	2017-10-13	2025-05-13	オプナバイオソシエテアノニム	キナーゼを調節するための化合物の固体形態
AR113922A1 (es)	2017-12-08	2020-07-01	Incyte Corp	Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
IL276302B2 (en)	2018-01-30	2023-11-01	Incyte Corp	Procedures for preparing [1-(3-fluoro-2-(trifluoromethyl(isonicotinyl}piperidine-4-one)
EP4424328A3 (en)	2018-03-30	2024-12-04	Incyte Corporation	Treatment of hidradenitis suppurativa using jak inhibitors
JP7458406B2 (ja)	2018-12-21	2024-03-29	セルジーンコーポレーション	Ｒｉｐｋ２のチエノピリジン阻害剤
CN114364798A (zh)	2019-03-21	2022-04-15	欧恩科斯欧公司	用于治疗癌症的Dbait分子与激酶抑制剂的组合
US20220401436A1 (en)	2019-11-08	2022-12-22	INSERM (Institute National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
PE20230251A1 (es)	2019-11-22	2023-02-07	Incyte Corp	Terapia de combinacion que comprende un inhibidor de alk2 y un inhibidor de jak2
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
KR102818206B1 (ko) *	2021-07-12	2025-06-11	한양대학교 에리카산학협력단	인다졸일 벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB966264A (en)	1961-08-31	1964-08-06	Distillers Co Yeast Ltd	Production of alkyl pyridines
GB1141949A (en) *	1966-02-23	1969-02-05	Sterling Drug Inc	7-azaindole derivatives
US3992392A (en) *	1973-04-27	1976-11-16	The Ohio State University Research Foundation	Synthesis of indoles from anilines and intermediates therein
EP0405602A1 (en)	1989-06-30	1991-01-02	Laboratorios Vinas S.A.	New Zinc derivatives of anti-inflammatory drugs having improved therapeutic activity
US5202108A (en) *	1990-10-12	1993-04-13	Analytical Development Corporation	Process for producing ferrate employing beta-ferric oxide
SE9100920D0 (sv)	1991-03-27	1991-03-27	Astra Ab	New active compounds
FR2687402B1 (fr)	1992-02-14	1995-06-30	Lipha	Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
JP3119758B2 (ja)	1993-02-24	2000-12-25	日清製粉株式会社	７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
US6756388B1 (en)	1993-10-12	2004-06-29	Pfizer Inc.	Benzothiophenes and related compounds as estrogen agonists
WO1995033748A1 (en) *	1994-06-09	1995-12-14	Smithkline Beecham Corporation	Endothelin receptor antagonists
US5521213A (en)	1994-08-29	1996-05-28	Merck Frosst Canada, Inc.	Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5589482A (en)	1994-12-14	1996-12-31	Pfizer Inc.	Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
GB2298199A (en)	1995-02-21	1996-08-28	Merck Sharp & Dohme	Synthesis of azaindoles
FR2732969B1 (fr) *	1995-04-14	1997-05-16	Adir	Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR004010A1 (es)	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos
CN1230185A (zh)	1996-07-13	1999-09-29	葛兰素集团有限公司	双环芳杂环化合物用作蛋白质酪氨酸激酶的抑制剂
EP0927167A1 (en)	1996-08-14	1999-07-07	Warner-Lambert Company	2-phenyl benzimidazole derivatives as mcp-1 antagonists
US5783969A (en)	1996-09-04	1998-07-21	Motorola, Inc.	Method and system for preventing an amplifier overload condition in a hybrid matrix amplifier array
US6180643B1 (en) *	1996-11-19	2001-01-30	Amgen Inc.	Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
GB9708235D0 (en) *	1997-04-23	1997-06-11	Ciba Geigy Ag	Organic compounds
WO1998047899A1 (en) *	1997-04-24	1998-10-29	Ortho-Mcneil Corporation, Inc.	Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
CN1264381A (zh) *	1997-08-05	2000-08-23	辉瑞产品公司	4－氨基吡咯并(3,2－d)嘧啶作为神经肽Y受体拮抗药
TR200001079T2 (tr) *	1997-10-20	2000-07-21	F.Hoffmann-La Roche Ag	Bisiklik kinaz inhibitörleri.
AU3210799A (en) *	1998-04-02	1999-10-25	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
US6025366A (en)	1998-04-02	2000-02-15	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
JP2002510628A (ja)	1998-04-02	2002-04-09	メルクエンドカムパニーインコーポレーテッド	性腺刺激ホルモン放出ホルモン拮抗薬
JP2002510684A (ja)	1998-04-02	2002-04-09	メルクエンドカムパニーインコーポレーテッド	性腺刺激ホルモン放出ホルモン拮抗薬
JP2002510631A (ja)	1998-04-02	2002-04-09	メルクエンドカムパニーインコーポレーテッド	性腺刺激ホルモン放出ホルモン拮抗薬
JP2002510629A (ja)	1998-04-02	2002-04-09	メルクエンドカムパニーインコーポレーテッド	性腺刺激ホルモン放出ホルモン拮抗薬
CA2330557A1 (en)	1998-05-12	1999-11-18	Robert Emmett Mcdevitt	Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6673797B1 (en)	1998-05-26	2004-01-06	Chugai Seiyaku Kabushiki Kaisha	Heterocyclic indole derivatives and mono- or diazaindole derivatives
US6232320B1 (en)	1998-06-04	2001-05-15	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
CZ439199A3 (cs) *	1998-07-10	2000-07-12	Pfizer Products Inc.	4-Aminopyrrol(3^-d)pyrimidiny jako antagonisty receptoru neuropeptidu Y
DE69928414T2 (de) *	1998-09-18	2006-08-03	Abbott Gmbh & Co. Kg	4-aminopyrrolopyrimidine als kinaseinhibitoren
ATE277896T1 (de)	1998-12-31	2004-10-15	Aventis Pharma Inc	Alpha-substituierung von ungeschützten beta- aminoestern
AU5314900A (en)	1999-06-04	2000-12-28	Elan Pharma International Limited	Compositions and methods for inhibiting cell death
US6207699B1 (en)	1999-06-18	2001-03-27	Richard Brian Rothman	Pharmaceutical combinations for treating obesity and food craving
PE20010306A1 (es)	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6387900B1 (en)	1999-08-12	2002-05-14	Pharmacia & Upjohn S.P.A.	3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
DE19944051A1 (de)	1999-09-14	2001-03-15	Wilke Heinrich Hewi Gmbh	Verriegelungsvorrichtung
DE19951360A1 (de)	1999-10-26	2001-05-03	Aventis Pharma Gmbh	Substituierte Indole
NZ519121A (en)	1999-12-24	2004-05-28	Aventis Pharma Ltd	Azaindoles useful as Syk kinase inhibitors
YU54202A (sh)	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
MXPA02007957A (es)	2000-02-17	2002-11-29	Amgen Inc	Inhibidores de cinasas.
US6264966B1 (en)	2000-02-22	2001-07-24	Concat, Ltd.	Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury
JP2003523390A (ja)	2000-02-25	2003-08-05	メルクエンドカムパニーインコーポレーテッド	チロシンキナーゼ阻害薬
DE10009000A1 (de)	2000-02-25	2001-08-30	Basf Ag	Verfahren zur Herstellung substituierter Indole
GB0007657D0 (en)	2000-03-29	2000-05-17	Celltech Therapeutics Ltd	Chemical compounds
JP2004501083A (ja)	2000-04-18	2004-01-15	アゴーロン・ファーマシューティカルズ・インコーポレイテッド	プロテインキナーゼを阻害するためのピラゾール
WO2001082930A1 (en) *	2000-05-03	2001-11-08	Tularik Inc.	Pyrazole antimicrobial agents
AU2001259707A1 (en)	2000-06-14	2001-12-24	Warner Lambert Company	6,5-fused bicyclic heterocycles
US6407259B1 (en)	2000-07-28	2002-06-18	Pfizer Inc.	Process for the preparation of pyrazoles
US6897231B2 (en)	2000-07-31	2005-05-24	Signal Pharmaceuticals, Inc.	Indazole derivatives as JNK inhibitors and compositions and methods related thereto
JP2004509115A (ja)	2000-09-15	2004-03-25	バーテックス　ファーマシューティカルズ　インコーポレイテッド	プロテインキナーゼインヒビターとして有用なピラゾール化合物
GB0115109D0 (en)	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds

2000
- 2000-12-27 NZ NZ519121A patent/NZ519121A/en not_active IP Right Cessation
- 2000-12-27 MX MXPA02006338A patent/MXPA02006338A/es active IP Right Grant
- 2000-12-27 PL PL355819A patent/PL209572B1/pl unknown
- 2000-12-27 CA CA2699568A patent/CA2699568C/en not_active Expired - Fee Related
- 2000-12-27 CA CA2395593A patent/CA2395593C/en not_active Expired - Fee Related
- 2000-12-27 CZ CZ20080557A patent/CZ301751B6/cs not_active IP Right Cessation
- 2000-12-27 KR KR1020077009139A patent/KR100910488B1/ko not_active Expired - Fee Related
- 2000-12-27 SK SK5027-2011A patent/SK288019B6/sk not_active IP Right Cessation
- 2000-12-27 HK HK03102024.3A patent/HK1050191B/en not_active IP Right Cessation
- 2000-12-27 AU AU22094/01A patent/AU777717B2/en not_active Ceased
- 2000-12-27 CN CNB008175950A patent/CN100379734C/zh not_active Expired - Fee Related
- 2000-12-27 KR KR1020027008150A patent/KR100755622B1/ko not_active Expired - Fee Related
- 2000-12-27 EA EA200200707A patent/EA005212B1/ru not_active IP Right Cessation
- 2000-12-27 BR BR0017038-0A patent/BR0017038A/pt active Search and Examination
- 2000-12-27 EP EP00985695A patent/EP1263759B1/en not_active Expired - Lifetime
- 2000-12-27 HR HR20020547A patent/HRP20020547B1/xx not_active IP Right Cessation
- 2000-12-27 SK SK901-2002A patent/SK287882B6/sk not_active IP Right Cessation
- 2000-12-27 HU HU0203895A patent/HUP0203895A3/hu unknown
- 2000-12-27 AP AP2006003492A patent/AP1917A/xx active
- 2000-12-27 AP APAP/P/2002/002516A patent/AP1587A/en active
- 2000-12-27 EP EP08162392A patent/EP1990343B1/en not_active Expired - Lifetime
- 2000-12-27 CN CNA2004100789697A patent/CN1615873A/zh active Pending
- 2000-12-27 CZ CZ20022207A patent/CZ301750B6/cs not_active IP Right Cessation
- 2000-12-27 WO PCT/GB2000/004993 patent/WO2001047922A2/en not_active Ceased
- 2000-12-27 IL IL15038800A patent/IL150388A0/xx unknown
- 2000-12-27 OA OA1200200199A patent/OA12514A/en unknown
- 2000-12-27 DZ DZ003377A patent/DZ3377A1/xx active
- 2000-12-27 EE EEP200200343A patent/EE05180B1/xx not_active IP Right Cessation
2002
- 2002-06-17 MA MA26692A patent/MA26857A1/fr unknown
- 2002-06-18 BG BG106836A patent/BG66066B1/bg unknown
- 2002-06-21 NO NO20023032A patent/NO323766B1/no not_active IP Right Cessation
- 2002-06-24 US US10/178,667 patent/US6770643B2/en not_active Expired - Lifetime
- 2002-06-24 IL IL150388A patent/IL150388A/en not_active IP Right Cessation
2004
- 2004-04-20 US US10/827,978 patent/US7227020B2/en not_active Expired - Lifetime
2006
- 2006-12-27 NO NO20066017A patent/NO330747B1/no not_active IP Right Cessation
2008
- 2008-08-21 IL IL193615A patent/IL193615A0/en unknown
2010
- 2010-03-18 BG BG10110623A patent/BG66176B1/bg unknown
- 2010-11-25 CY CY20101101074T patent/CY1110951T1/el unknown
2011
- 2011-09-08 JP JP2011195789A patent/JP5436507B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR20070050103A (ko)	2007-05-14
KR20020062663A (ko)	2002-07-26
EA200200707A1 (ru)	2003-02-27
IL150388A0 (en)	2002-12-01
CA2395593A1 (en)	2001-07-05
NO330747B1 (no)	2011-07-04
CA2395593C (en)	2011-08-02
NO323766B1 (no)	2007-07-02
PL209572B1 (pl)	2011-09-30
EP1990343A2 (en)	2008-11-12
NO20023032L (no)	2002-06-21
NO20023032D0 (no)	2002-06-21
AP1917A (en)	2008-11-12
HK1050191B (en)	2011-04-29
HK1050191A1 (en)	2003-06-13
CN1615873A (zh)	2005-05-18
BG66176B1 (bg)	2011-11-30
AP1587A (en)	2006-03-02
EA005212B1 (ru)	2004-12-30
SK288019B6 (sk)	2012-11-05
KR100910488B1 (ko)	2009-08-04
NZ519121A (en)	2004-05-28
EP1990343B1 (en)	2012-04-04
CZ301751B6 (cs)	2010-06-09
CA2699568A1 (en)	2001-07-05
CY1110951T1 (el)	2015-06-11
US6770643B2 (en)	2004-08-03
JP2012031181A (ja)	2012-02-16
IL193615A0 (en)	2009-05-04
SK287882B6 (sk)	2012-02-03
CA2699568C (en)	2013-03-12
EP1263759A2 (en)	2002-12-11
US20040009983A1 (en)	2004-01-15
EP1990343A3 (en)	2008-12-10
HUP0203895A2 (hu)	2003-02-28
CN1413213A (zh)	2003-04-23
CZ301750B6 (cs)	2010-06-09
BG66066B1 (bg)	2011-01-31
BR0017038A (pt)	2003-01-07
KR100755622B1 (ko)	2007-09-04
EP1263759B1 (en)	2010-09-08
CN100379734C (zh)	2008-04-09
IL150388A (en)	2010-11-30
BG106836A (bg)	2003-04-30
BG110623A (bg)	2010-07-30
AU777717B2 (en)	2004-10-28
MA26857A1 (fr)	2004-12-20
HRP20020547A2 (hr)	2005-10-31
US20040198737A1 (en)	2004-10-07
EE05180B1 (et)	2009-06-15
JP5436507B2 (ja)	2014-03-05
PL355819A1 (en)	2004-05-17
HRP20020547B1 (hr)	2011-06-30
US7227020B2 (en)	2007-06-05
OA12514A (en)	2006-05-29
SK9012002A3 (en)	2003-04-01
CZ20022207A3 (cs)	2002-11-13
WO2001047922A2 (en)	2001-07-05
DZ3377A1 (fr)	2001-07-05
MXPA02006338A (es)	2002-12-13
AP2006003492A0 (en)	2006-02-28
AP2002002516A0 (en)	2002-06-30
EE200200343A (et)	2003-06-16
HUP0203895A3 (en)	2004-09-28
WO2001047922A3 (en)	2002-01-17
AU2209401A (en)	2001-07-09

Publication	Publication Date	Title
DZ3377A1 (fr)	2001-07-05	Azaindoles
DE50010505D1 (de)	2005-07-14	Gurtaufrollersystem
DE122007000064I2 (de)	2010-03-25	Erythropoietinkonjugate
DE19983871T1 (de)	2002-01-31	Fönvorrichtung
DE10084676T1 (de)	2003-04-30	Einmallanzettvorrichtung
DE60022893D1 (de)	2006-02-09	Naphthyridinverbindungen
DE50002834D1 (de)	2003-08-14	Handstempel
ATE357433T1 (de)	2007-04-15	4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de)	2005-07-15	4-pyridinyl-n-acyl-l-phenylalanine
DE50009570D1 (de)	2005-03-31	Wechselcorrugator
DE50007953D1 (de)	2004-11-04	Beleuchtungsanordung
DE50008613D1 (de)	2004-12-16	Sicherungsring
DE50000805D1 (de)	2003-01-09	Aufsitzspanner
DE50006899D1 (de)	2004-07-29	Antistatikum
DE10085008T1 (de)	2002-10-10	Oberflächenbehandlungsdüse
DE50012482D1 (de)	2006-05-18	Tibiamarknagel
DE50003660D1 (de)	2003-10-16	Diacylhydrazinderivate
DE50003259D1 (de)	2003-09-18	Textilie
DE50006013D1 (de)	2004-05-13	Anschlagpuffer
DE19983890T1 (de)	2002-03-07	Ventiltaktgebungsjustiereinrichtung
DE50008429D1 (de)	2005-01-20	Kraftstofffraktioniereinrichtung
DE50001640D1 (de)	2003-05-08	Nahfeldoptische untersuchungsvorrichtung
DE50006759D1 (de)	2004-07-15	Piperidinalkohole
DE50009208D1 (de)	2005-02-17	Hydroxyphenylvinylthiazole
ATE440824T1 (de)	2009-09-15	Nitro-sulfobenzamide

Legal Events

Date	Code	Title	Description
2015-07-27	MM1K	Lapsed by not paying the annual fees